DK0582368T3 - Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet - Google Patents

Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet

Info

Publication number
DK0582368T3
DK0582368T3 DK93304102T DK93304102T DK0582368T3 DK 0582368 T3 DK0582368 T3 DK 0582368T3 DK 93304102 T DK93304102 T DK 93304102T DK 93304102 T DK93304102 T DK 93304102T DK 0582368 T3 DK0582368 T3 DK 0582368T3
Authority
DK
Denmark
Prior art keywords
treatment
nervous system
central nervous
system disorders
alkyl
Prior art date
Application number
DK93304102T
Other languages
Danish (da)
English (en)
Inventor
David Edward Tupper
John Fairhurst
Terrence Michael Hotten
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211379A external-priority patent/GB9211379D0/en
Priority claimed from GB939309025A external-priority patent/GB9309025D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0582368T3 publication Critical patent/DK0582368T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK93304102T 1992-05-29 1993-05-26 Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet DK0582368T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929211379A GB9211379D0 (en) 1992-05-29 1992-05-29 Pharmaceutical compounds
GB939309025A GB9309025D0 (en) 1993-04-30 1993-04-30 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
DK0582368T3 true DK0582368T3 (da) 2001-02-05

Family

ID=26300951

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93304102T DK0582368T3 (da) 1992-05-29 1993-05-26 Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet

Country Status (21)

Country Link
EP (1) EP0582368B1 (fr)
JP (1) JP3219541B2 (fr)
CN (1) CN1043994C (fr)
AT (1) ATE198891T1 (fr)
AU (1) AU668159B2 (fr)
CA (1) CA2097016A1 (fr)
CZ (1) CZ282783B6 (fr)
DE (1) DE69329887T2 (fr)
DK (1) DK0582368T3 (fr)
ES (1) ES2153373T3 (fr)
FI (1) FI101538B1 (fr)
GR (1) GR3035587T3 (fr)
HU (1) HU218278B (fr)
IL (1) IL105827A (fr)
MX (1) MX9303124A (fr)
MY (1) MY109943A (fr)
NO (1) NO305125B1 (fr)
NZ (1) NZ247703A (fr)
PT (1) PT582368E (fr)
RU (1) RU2125574C1 (fr)
TW (1) TW268005B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
BR9708246A (pt) * 1996-03-25 1999-07-27 Lilly Co Eli Metodo para tratamento de dor
IL126063A (en) * 1996-03-25 2002-04-21 Lilly Co Eli Medicinal products containing ulanzapine for the treatment of migraine pain
CZ296263B6 (cs) * 1996-03-25 2006-02-15 Eli Lilly And Company Farmaceutická kompozice pro lécení bolesti a jejípouzití
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
ID21924A (id) * 1996-09-23 1999-08-12 Lilly Co Eli Olanzapin dihidrat d
CN1230883A (zh) * 1996-09-24 1999-10-06 伊莱利利公司 包衣颗粒制剂
AU2013305907B2 (en) 2012-08-21 2018-01-18 Saladax Biomedical Inc. Antibodies to quetiapine and use thereof
CA2882597C (fr) 2012-08-21 2020-04-14 Ortho-Clinical Diagnostics, Inc. Anticorps diriges contre des haptenes de quetiapine et leur utilisation
EP2888287A4 (fr) 2012-08-21 2016-04-20 Ortho Clinical Diagnostics Inc Anticorps dirigés contre des haptènes de palipéridone et leur utilisation
JP6339569B2 (ja) 2012-08-21 2018-06-06 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンへの抗体及びその使用
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
CA2882596C (fr) 2012-08-21 2019-05-14 Ortho-Clinical Diagnostics, Inc. Anticorps diriges contre l'olanzapine et leur utilisation
TR201910347T4 (tr) 2012-08-21 2019-07-22 Janssen Pharmaceutica Nv Olanzapin haptenlerine yönelik antikorlar ve bunların kullanımı.
EP2888234B1 (fr) 2012-08-21 2017-12-06 Janssen Pharmaceutica NV Haptènes d'aripiprazole et leur utilisation dans des dosages immunologiques
WO2014031587A1 (fr) * 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptènes de l'olanzipine
TR201809424T4 (tr) 2012-08-21 2018-07-23 Janssen Pharmaceutica Nv Risperidon ve paliperidon haptenleri.
CN104736567B (zh) 2012-08-21 2019-09-03 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
PT2888258T (pt) 2012-08-21 2019-08-21 Janssen Pharmaceutica Nv Hapteno de paliperidona
CN104736561B (zh) 2012-08-21 2018-06-12 詹森药业有限公司 帕潘立酮的抗体及其用途
CN108517014A (zh) 2012-08-21 2018-09-11 詹森药业有限公司 利培酮半抗原的抗体及其用途
ES2645433T3 (es) 2012-08-21 2017-12-05 Janssen Pharmaceutica, N.V. Haptenos de quetiapina para su uso en inmunoensayos
WO2017106508A1 (fr) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Anticorps dirigés contre la quétiapine et utilisation associée
US10444250B2 (en) 2015-12-17 2019-10-15 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
SE7610219L (sv) * 1975-09-24 1977-03-25 Sandoz Ag Nya dibenso /b,e//1,4/ diazepiner
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
NO305125B1 (no) 1999-04-06
EP0582368A1 (fr) 1994-02-09
HU9301579D0 (en) 1993-09-28
CZ102493A3 (en) 1993-12-15
IL105827A0 (en) 1993-09-22
DE69329887D1 (de) 2001-03-01
ATE198891T1 (de) 2001-02-15
CN1043994C (zh) 1999-07-07
IL105827A (en) 1997-02-18
JPH0687862A (ja) 1994-03-29
CA2097016A1 (fr) 1993-11-30
PT582368E (pt) 2001-05-31
NO931917L (no) 1993-11-30
NZ247703A (en) 1995-07-26
ES2153373T3 (es) 2001-03-01
MY109943A (en) 1997-10-31
MX9303124A (es) 1993-11-01
CN1085903A (zh) 1994-04-27
HU218278B (en) 2000-07-28
FI101538B (fi) 1998-07-15
RU2125574C1 (ru) 1999-01-27
AU668159B2 (en) 1996-04-26
GR3035587T3 (en) 2001-06-29
NO931917D0 (no) 1993-05-26
FI932445A (fi) 1993-11-30
FI101538B1 (fi) 1998-07-15
HUT66180A (en) 1994-09-28
TW268005B (fr) 1996-01-11
DE69329887T2 (de) 2001-05-23
FI932445A0 (fi) 1993-05-28
AU3980793A (en) 1993-12-02
CZ282783B6 (cs) 1997-10-15
JP3219541B2 (ja) 2001-10-15
EP0582368B1 (fr) 2001-01-24

Similar Documents

Publication Publication Date Title
DK0582368T3 (da) Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet
ATE103812T1 (de) Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
ES2143526T3 (es) Derivados de amida que tienen actividad antihipercolesterolemica, su preparacion y sus usos terapeuticos.
ES2054020T3 (es) Compuestos biologicamente activos.
FI821598L (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 1-alkyl-2-aminotetralinderivat
NO893205L (no) Kjemiske forbindelser.
MX9202803A (es) Nuevos compuestos de benzopirano y procedimiento para su preparacion.
MD1560G2 (ro) Compuşi ciclici, compoziţii farmaceutice pe baza lor şi metode de tratament al infecţiilor sau bolilor provocate de retrovirusuri
MX9300875A (es) Procedimiento para la preparacion de compuestos azabiciclicos.
DK0594099T3 (da) Fremgangsmåde til rensning af rå clavulansyre
DE69823240D1 (de) Immunmodulierende arzneimittelzusammenstellung
ATE98230T1 (de) Indolderivate.
DE69327077D1 (de) Carbamoylpyrrolidon-Derivate zur Behandlung von Depressionen und cerebrovasculären Störungen
DE69527854D1 (de) Derivate substituierter amidinonaphthylester
PT889044E (pt) Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
ATE71364T1 (de) Fluor enthaltende vitamin-d2-derivate.
DK0501442T3 (da) 8-Chlor-benzothiazepin-forbindelse til forebyggelse og behandling af følgerne af cerebral nekrose af nerveceller
ES2133095A1 (es) Acidos alquilidenglutaminicos con propiedades farmaceuticas.